Prior Research Sample Clauses

Prior Research. 2.2.1 The Parties acknowledge that Xxxxxx has performed certain Research Activities with respect to Collaboration Target 1 prior to the Original Agreement Execution Date, and agree that for purposes of this Agreement, [***]. 2.2.2 Under the Original Agreement, Kymera provided Sanofi (via the JRDC) a list of [***], for discussion by the JRDC. Kymera will provide a list of [***] to the JRDC at the first JRDC meeting after the Restatement Effective Date. 2.2.3 [***].
Sample 1Sample 2
Prior Research. Subject to EMCC's prior agreement, as evidenced by EMCC's execution of the statement set forth in Section 15.27 hereof, this Agreement shall supercede the CRDLA, and the CRDLA is terminated, as of the Effective Date. All work remaining to be performed under the CRDLA with respect to the * Research Projects active under the CRDLA as of the Effective Date, as described in Section 2.01, shall be performed under this Agreement, and shall be managed pursuant to the provisions of Article 3. Research activities performed under the CRDLA (including research activities performed under the Interim Agreement) and the Interim Alliance Agreement shall be considered to be work performed in the Research Program for all purposes of this Agreement, including without limitation license payment obligations set forth in Article 8 of this Agreement; provided, however, that payments made to Symyx Tech under the CRDLA, the Interim Agreement and the Interim Alliance Agreement shall not offset or reduce the payments provided for under this Agreement, except as expressly set forth in Sections 8.01.3, 8.05 and 8.06. In addition, Confidential Information supplied by one party to another party under the CRDLA, the Interim Agreement and the Interim Alliance Agreement shall be considered as Confidential Information supplied under this Agreement and shall be governed by the provisions of Article 11 below.
Sample 1
Prior Research. First of all, we defined the core goal the platform should fulfill. As described in the initial project proposal, a well-functioning platform should serve to close the gap between investors and innovators involved in the market for climate adaptation and disaster risk reduction solutions and give structural guidance and support in doing this, outlasting the BRIGAID project period. In order to achieve these goals, the platform would need to be valuable and useful to both the innovators and the investors, and develop a sustainable income source for itself at the same time. In order to serve the innovators, the platform should give the innovators exposure to sources of funding that they would otherwise have trouble reaching. However, in order to allow for this, investors should benefit from the platform as well, by being presented with innovators that are of sufficient quality and that provide opportunities and value to the investor beyond those that he or she will have easy access to through their own channels. Though only broadly defined here, these goals are considered a minimum requirement for the platform to be successful, because providing value to these two classes of users is necessary in order for it to start creating the desired impact. This requirement does introduce some challenges that need to be tackled. First of all, any solution that is suggested that offers this value should be built to outlast the BRIGAID project period. This requires the platform to be financially self-sustaining. Related to this, the platform should make sure to fill a niche, that provides value that is not already offered by existing platforms, specifically providing benefit to the innovators that fall within the scope of BRIGAID. This is required, not only to achieve the core goals of the platform, but also to ensure financial viability. It speaks to reason to obtain this unique value from the core value that the BRIGAID market analysis and business development support currently offers innovators. However, this value is heavily reliant on the professional support that innovators currently receive from the BRIGAID partners - which is currently not accounted for after the end of the project. The following paragraphs show the results of the competitor analysis that was performed in order to find the gaps where the Funding Platform might add unique value; the feedback gathered from potential platform users, both on the side of the investor and the innovator; key insights fro...
Sample 1
Prior Research. 10.1 If I have based any of my research for the Project on work I may have performed prior to being assigned to the Project, I must bring this to the attention of my Faculty Supervisor so that UPEI and I can reach agreement on the ownership or protection of prior work. Although not a requirement, it is strongly recommended that Three Oaks Innovations Inc. be involved in these discussions.
Sample 1
Prior Research. The presence of sentencing disparities along the lines of ethnicity/race has attracted immense scholarly attention, with most attention devoted to the preferential treat- ment of White versus Black defendants at sentencing in the U.S. (Bridges and Xxxxx, 1998; Xxxxx, 0000; Xxxxx, 0000; Radelet, 1981; Xxxxxxx and Xxxxxxxxx, 1997; Xxxxxxxx- xxxxx et al., 1998; Thomson and Zingraff, 1981; Xxxxx and Xxxxxx, 1996). Recently, a growing literature also focuses theoretically and empirically on Hispanic defendants in the U.S. to provide for White-Black-Hispanic comparisons (e.g., Xxxxxxxxxxxxx and Xxxxxx, 2001; Warren, Chiricos, and Xxxxx, 2012). On the whole, effects of race and ethnicity tend to be small and, in certain contexts, affect judges’ decisions in sentenc- ing only indirectly or in combination with other offender characteristics, such as age, employment, and sex (Xxxxxxxxxxxxx et al., 1998; Xxxxx and Xxxxxxxx, 2000).1 As sug- gested by Xxxxx (2009: 190) about this work,
Sample 1
Prior Research. The presence of sentencing disparities along the lines of ethnicity/race has attracted immense scholarly attention, with most attention devoted to the preferential treat- ment of White versus Black defendants at sentencing in the U.S. (Xxxxxxx and Xxxxx, 1998; Xxxxx, 2000; Xxxxx, 1998; Xxxxxxx, 1981; Xxxxxxx and Xxxxxxxxx, 1997; Xxxxxxxx- xxxxx et al., 1998; Xxxxxxx and Xxxxxxxx, 1981; Xxxxx and Xxxxxx, 1996). Recently, a growing literature also focuses theoretically and empirically on Hispanic defendants in the U.S. to provide for White-Black-Hispanic comparisons (e.g., Xxxxxxxxxxxxx and Xxxxxx, 2001; Xxxxxx, Xxxxxxxx, and Xxxxx, 2012). On the whole, effects of race and ethnicity tend to be small and, in certain contexts, affect judges’ decisions in sentenc- ing only indirectly or in combination with other offender characteristics, such as age, employment, and sex (Xxxxxxxxxxxxx et al., 1998; Xxxxx and Xxxxxxxx, 2000).1 As sug- gested by Xxxxx (2009: 190) about this work, The fact that . . . African Americans and . . . Hispanics were more likely than whites to be sentenced to prison, even after taking crime seriousness and prior criminal record into account, suggests that racial discrimination in sentencing is not a thing of the past. Limited work on other minority groups, such as Native American offenders (e.g.,Xxxx- rez and Xxxxxxx, 1996) or Asian offenders (Xxxxxxx and Xxxxxxxxx, 2009), and work in other contexts, such as Australia and Canada (Xxxx and Xxxxxxxx, 2011; Xxxxxxx and Xxxx, 1997; Xxxxxxxx and Xxxxxxxxxxx, 2007;Xxxxxxxx, 1999; but see Xxxxx and Xxxxxx, 2008) reaches similar conclusions. Also in Europe, a long research tradition focuses on sentenc- ing. In particular, scholars have focused on normative issues surrounding aggravating and mitigating factors in sentencing (e.g., Xxxxxxx, 2011; Xxxxxx, 2014); public opinions regarding sentencing practices (Xxxxx and Xxxxxxx, 1999; Xxxxxxxx and Xxxxxx, 2011); and consistency and discretion within criminal justice systems (Xx Xxxxxxx, 2000; Xxxxx and Xxxxxxxx, 2014; Xxxx-Xxxxxxx, 2015; Xxxxxxxˇxx, 2013). But, in Europe, with its unique immigrant groups, quantitative multivariate research on the effects of race or ethnicity on punishment decisions is virtually non-existent.2 Research is impeded by the lack of available data on offenders’ ethnicity (Xxxxx, 2014). Although it is common knowl- edge that some immigrant groups are overrepresented in European prisons, it is unclear whether this is caused ...
Sample 1
Prior Research. 2.2.1 The Parties acknowledge that Kymera has performed certain Research Activities with respect to Collaboration Target 1 prior to the Execution Date, and agree that for purposes of this Agreement, [***]. 2.2.2 Within [***] after the Effective Date, Kymera will provide Sanofi (via the JRDC) a list of [***], for discussion by the JRDC.
Sample 1

Related to Prior Research

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Manufacturing Technology Transfer Except as the Committee ------------ --------------------------------- may otherwise agree in writing, in order to effectuate an orderly transition of the uninterrupted availability of Product to LILLY for purposes contemplated under this Agreement, MEGABIOS, at least ninety (90) days prior to completion of the Project or completion of Phase I Clinical Trials, whichever is earlier, shall transfer to LILLY all information and instructions concerning the manufacturing process and related matters in MEGABIOS' possession which may be necessary for LILLY to manufacture Product (including information regarding obtaining necessary Lipids related thereto) for clinical trials and commercialization as contemplated hereunder including, but not limited to, analytical and manufacturing methods. MEGABIOS shall also provide assistance (in the form of consultation) to LILLY with respect to manufacturing matters for a period of [ * ] months after completion of the initial transfer of information and instructions as provided below. Such transfer and assistance by MEGABIOS will be referred to herein as the "Manufacturing Transfer." All such information, methods and instructions transferred to LILLY under this Section 4.3 shall be referred to herein as the "Manufacturing Information," and shall be maintained in confidence by LILLY pursuant to Section 7.1, except that LILLY's obligation to maintain in confidence such Manufacturing Information shall survive for ten (10) years following expiration or termination of this Agreement. LILLY agrees that it will use all such transferred Manufacturing Information only for the manufacture of the Products and shall not disclose or transfer such Manufacturing Information to any third party manufacturer except as provided in Section 2.10. MEGABIOS shall provide, and bear its costs for, up to [ * ] FTEs for a period of up to [ * ] months [ * ] in aggregate) to accomplish the Manufacturing Transfer. Such FTEs, at LILLY's request, shall include visits to LILLY's facilities by MEGABIOS personnel including up to [ * ] from MEGABIOS' head of manufacturing. MEGABIOS shall furnish any additional reasonable assistance beyond the assistance described above regarding manufacturing matters that LILLY may request and that MEGABIOS is able to provide, for up to [ * ] after the initial transfer of Manufacturing Information, providing that LILLY [ * ] incurred with respect to such additional assistance.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Research Program The term “